NASC (Nascent Pharma Holdings) Cyclically Adjusted PB Ratio: (As of Jul. 09, 2026)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.01
View Full Analysis

What is Nascent Pharma Holdings Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nascent Pharma Holdings  (OTCPK:NASC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Nascent Pharma Holdings Cyclically Adjusted PB Ratio Related Terms


Nascent Pharma Holdings Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings Cyclically Adjusted PB Ratio Chart

Nascent Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nascent Pharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NASC vs ALID, CPMD, PLSH: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Pharma Holdings Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nascent Pharma Holdings's Cyclically Adjusted PB Ratio falls into.


NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nascent Pharma Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Nascent Pharma Holdings's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.257/315.3010*315.3010
=-0.257

Current CPI (Sep. 2024) = 315.3010.

Nascent Pharma Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201412 0.388 234.812 0.521
201503 2.061 236.119 2.752
201506 0.778 238.638 1.028
201509 5.370 237.945 7.116
201512 -0.031 236.525 -0.041
201603 0.000 238.132 0.000
201606 -6.563 241.018 -8.586
201609 -9.250 241.428 -12.080
201612 -19.344 241.432 -25.263
201703 -15.029 243.801 -19.437
201706 -25.139 244.955 -32.358
201709 -19.763 246.819 -25.246
201712 -39.480 246.524 -50.494
201803 -20.327 249.554 -25.682
201806 -32.519 251.989 -40.689
201809 -15.104 252.439 -18.865
201812 -10.908 251.233 -13.690
201903 -2.885 254.202 -3.578
201906 -2.742 256.143 -3.375
201909 6.329 256.759 7.772
201912 6.207 256.974 7.616
202003 0.634 258.115 0.774
202006 -2.610 257.797 -3.192
202009 -6.877 260.280 -8.331
202012 -88.030 260.474 -106.559
202103 -0.770 264.877 -0.917
202106 -2.285 271.696 -2.652
202109 0.037 274.310 0.043
202112 -8.122 278.802 -9.185
202203 0.221 287.504 0.242
202206 0.033 296.311 0.035
202209 -0.965 296.808 -1.025
202212 -1.259 296.797 -1.337
202303 -1.071 301.836 -1.119
202306 -1.345 305.109 -1.390
202309 -0.305 307.789 -0.312
202312 -0.282 306.746 -0.290
202403 -0.297 312.332 -0.300
202406 -0.233 314.175 -0.234
202409 -0.257 315.301 -0.257

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price